With drug costs being the top barrier to successful outcomes in value-based care payment models, lower-cost biosimilars can play a role in achieving cost savings while maintaining high quality of care.How practices can leverage cost savings:
The greater availability of biosimilars may offer the opportunity to improve quality of care while reducing costs.
*From a survey of 530 community oncologists in early 2019.
Davio, K. October 2018. ODAC Hearing Shows the Mood on Biosimilars Is Changing, Oncologist Says. https://www.centerforbiosimilars.com/news/odac-hearing-shows-the-moodon-biosimilars-is-changing-oncologistsays